180 related articles for article (PubMed ID: 31645793)
1. A Case of Recurrent Lobar Intracerebral Hemorrhage in the Setting of Phosphodiesterase-5 Inhibitor Use.
Lucchese SA; Dhaliwal AS; Kaur A; Qi L
Mo Med; 2019; 116(5):400-403. PubMed ID: 31645793
[TBL] [Abstract][Full Text] [Related]
2. Association of Transient Colorblindness With Sildenafil and Tadalafil.
Rosen SM; Kaja S; De Alba F
JAMA Ophthalmol; 2019 Jan; 137(1):117-118. PubMed ID: 30286227
[No Abstract] [Full Text] [Related]
3. A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
van Landingham SW; Singman EL
Am Orthopt J; 2015; 65():109-14. PubMed ID: 26564936
[TBL] [Abstract][Full Text] [Related]
4. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
Magee AG; Makhecha S; Bentley S
Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
[TBL] [Abstract][Full Text] [Related]
5. Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries.
Mulhall JP; Hassan TA; Rienow J
Int J Clin Pract; 2018 Apr; 72(4):e13074. PubMed ID: 29460994
[TBL] [Abstract][Full Text] [Related]
6. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
7. Influencing Factors for Erectile Dysfunction of Young Adults with No Response to PDE5i.
Wang J; Wang YL; He Y; Li S; Zhang YP; Cheng YB; Guo JL; Sun L; Xin Y; Tang Y; Zhu ZH; Zeng HQ
Curr Med Sci; 2021 Jun; 41(3):529-534. PubMed ID: 34169423
[TBL] [Abstract][Full Text] [Related]
8. Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors.
Nagasawa S; Saka K; Yamagishi Y; Yajima D; Chiba F; Yamaguchi R; Torimitsu S; Iwase H
Leg Med (Tokyo); 2021 Feb; 48():101815. PubMed ID: 33264696
[TBL] [Abstract][Full Text] [Related]
9. Subarachnoid and intracerebral hemorrhage after alcohol ingestion and illicit use of sildenafil.
Antar V; Sutpideler N; Baran O; Bitirak G
Turk Neurosurg; 2015; 25(3):485-7. PubMed ID: 26037192
[TBL] [Abstract][Full Text] [Related]
10. PDE-5 inhibitors: clinical points.
Doumas M; Lazaridis A; Katsiki N; Athyros V
Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
[TBL] [Abstract][Full Text] [Related]
11. [Central serous chorioretinopathy following the use of phosphodiesterase 5 inhibitors].
Smal C; Lepièce G; Bonnet S
Rev Med Liege; 2017 Nov; 72(11):475-477. PubMed ID: 29171944
[TBL] [Abstract][Full Text] [Related]
12. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
[TBL] [Abstract][Full Text] [Related]
13. [Current role of sildenafil in the management of erectile dysfunction].
Akhvlediani ND; Matyukhov IP
Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
[TBL] [Abstract][Full Text] [Related]
14. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
15. Fourth Cranial Nerve Palsy Associated With Sildenafil Citrate.
Lee Y; Park KA; Oh SY; Min JH; Kim BJ
J Neuroophthalmol; 2021 Mar; 41(1):e79-e80. PubMed ID: 32235216
[No Abstract] [Full Text] [Related]
16. Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.
Montorsi F; Oelke M; Henneges C; Brock G; Salonia A; d'Anzeo G; Rossi A; Mulhall JP; Büttner H
Eur Urol; 2016 Sep; 70(3):529-37. PubMed ID: 26947602
[TBL] [Abstract][Full Text] [Related]
17. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
[TBL] [Abstract][Full Text] [Related]
18. Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil.
Glina S; Sotomayor M; Gatchalian E; Yaman O; Dyachkova Y; Markey C; Kopernicky V
J Sex Med; 2006 Mar; 3(2):309-19. PubMed ID: 16490025
[TBL] [Abstract][Full Text] [Related]
19. [PDE-5 inhibitors: patients preferences].
Efremov EA; Kasatonova EV; Melnik YI; Nikushina AA
Urologiia; 2017 Jul; (3):120-126. PubMed ID: 28845950
[TBL] [Abstract][Full Text] [Related]
20. Acute pancreatitis induced by Tadalafil: a case report.
Navabi SJ; Khosravifar M; Navabi SM; Heydari R
Clin J Gastroenterol; 2020 Jun; 13(3):459-464. PubMed ID: 31797202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
